Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer

BACKGROUND: The phase III EMILIA and TH3RESA trials demonstrated clinical benefits of trastuzumab emtansine (T-DM1) therapy in patients with previously treated HER2-positive metastatic breast cancer (MBC). Data from these and other trials showed that T-DM1–associated survival benefits were observed...

Descripción completa

Detalles Bibliográficos
Autores principales: Perez, Edith A., de Haas, Sanne Lysbet, Eiermann, Wolfgang, Barrios, Carlos H., Toi, Masakazu, Im, Young-Hyuck, Conte, Pier Franco, Martin, Miguel, Pienkowski, Tadeusz, Pivot, Xavier B., Burris, Howard A., Stanzel, Sven, Patre, Monika, Ellis, Paul Anthony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6543580/
https://www.ncbi.nlm.nih.gov/pubmed/31146717
http://dx.doi.org/10.1186/s12885-019-5687-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6543580/
https://www.ncbi.nlm.nih.gov/pubmed/31146717
http://dx.doi.org/10.1186/s12885-019-5687-0

Ejemplares similares